ROKIT Healthcare (KOSDAQ: 202600) is a publicly listed regenerative medicine company developing an AI-driven, autologous Kidney Regeneration Platform that integrates 3D bioprinting, patient-derived tissue therapy, and point-of-care manufacturing.

The platform has demonstrated significant preclinical success in ischemic and fibrotic kidney models, including renal fibrosis resolution, vascular remodeling, and functional tissue recovery. Building on these results, ROKIT is advancing its kidney program into a pilot clinical study, targeting global translational research and early clinical adoption through strategic partnerships.